DASL-HiCaP
07 Dec 2020
Trial Summary
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation and definitive or salvage radiation in very
Acronym:
DASL-HiCaP
ACTRN/NCT /ethics:
NCT04136353
Scientific title:
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
Sponsor / Cooperative group:
University of Sydney
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2020-01-31 |
| Anticipated End Date | 2028-07-31 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |